Glucosamine Periodontal Adjunctive Therapy

Overview

This study is the first evidence based work evaluated the systemic use of glucosamine as an adjunctive therapy to closed mechanical debridement in chronic periodontitis. The use of glucosamine sulphate was correlated with clinical outcomes and IL1-β level in the GCF of patients with moderate to advanced chronic periodontitis

Full Title of Study: “Glucosamine Sulphate as an Adjunctive Therapy to Closed Mechanical Debridement Reduced Gingival Cervicular Fluid IL-1β in Patients With Chronic Periodontitis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: February 2013

Detailed Description

Targeting the inflammatory response may be a rational approach to the medical treatment of chronic periodontitis. Glucosamine sulphate (GS) was proven to have anti-inflammatory actions with minimal side effect profile. Objectives; The main objectives of this study were to evaluate clinically the efficacy of GS; as a novel adjunctive host modulating agent in periodontal therapy and to investigate its effect on gingival crevicular fluid (GCF) level of IL-1β. Methods; Forty patients with moderate to severe chronic periodontitis (CP) were included in this study. They were randomly divided into two groups. Group I (G1) patients (n=20) received 500 mg GS capsules three times daily for 3 months following full mouth scaling and root planing (SRP), while group II (G2) patients (n=20) received a placebo for the same period following full mouth SRP. Clinical periodontal parameters and GCF IL-1β levels were analyzed at baseline and 3 months following therapy.

Interventions

  • Drug: glucosamine sulphate
    • group I (G1) patients received 500 mg glucosamine sulphate capsules (Glucosamine Compound) , three times daily for 3 months following initial cause related therapy. Group II patients were given placebo capsules( Lactose) for the same period following initial cause related therapy
  • Drug: lactose capsules

Arms, Groups and Cohorts

  • Active Comparator: glucosamine sulphate capsules
    • 500 mg Glucosamine Compound, three times daily for 3 months following initial cause related therapy.
  • Placebo Comparator: lactose capsules
    • lactose capsules three times daily for 3 months

Clinical Trial Outcome Measures

Primary Measures

  • gingival crevicular fluid IL-1β level
    • Time Frame: 0-3 months
    • baseline and after three months of Glucosamine Sulphate administration

Secondary Measures

  • probing depth
    • Time Frame: 0-3 months
    • the distance from the gingival margin to the base of the pocket was measured at baseline and 3 months after drug administration
  • clinical attachment level
    • Time Frame: 0-3 months
    • distance from cemento-enamel junction and base of the pocket was measured at baseline and 3 months after drug administration
  • gingival index
    • Time Frame: 0-3 months
    • gingival inflammation was measured by gingival index at baseline and 3 months after drug administration.
  • plaque index
    • Time Frame: 0-3 months
    • plaque deposits was measured by plaque index at baseline and 3 months after drug therapy

Participating in This Clinical Trial

Inclusion Criteria

1. good compliance with the plaque control instructions following initial therapy 2. each subject contributed a single premolar or molar tooth with interproximal probing depth ≥ 5 mm and clinical attachment loss ≥ 4 mm 3. teeth involved were all vital with score 0-1 mobility 4. availability for the follow-up and maintenance program; Exclusion Criteria:

1. no systemic diseases which could influence the outcome of therapy as evidenced by Burket's Oral Medicine health history questionnaire 2. absence of periodontal treatment for the previous year 3. absence of systemic medication or antibiotic treatment for the previous six months 4. absence of a smoking habit. 5. post menopausal, pregnant or breast feeding women were excluded from participating in the study. Patients with contraindications to glucosamine sulphate therapy e.g., hypersensitivity to any of the product's components or with inadequate compliance with the oral hygiene maintenance schedule were also excluded from the study.

Gender Eligibility: All

Minimum Age: 35 Years

Maximum Age: 48 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Ain Shams University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Mai Shafik Attia, lecturer of oral medicine and periodontology – Ain Shams University
  • Overall Official(s)
    • Ahmaed Y Gamal, Principal Investigator, Ainshams University
    • Hala A Elela, professer, Principal Investigator, Ainshams University
    • Mai S Attia, Lecturer, Principal Investigator, Al-Azhar University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.